Novartis announces data from Phase III studies of Gilenya at AAN

New data will be presented at the 65th annual meeting of the American Academy of Neurology, or AAN, that show continued innovation within the Novartis Multiple Sclerosis, or MS, portfolio. Growing clinical trial and real-world experience with Gilenya, the first once-daily oral therapy approved to treat people with relapsing MS,will be highlighted. Updates on studies of Gilenya in people with primary-progressive MS and the investigational agent BAF312 in people with secondary-progressive MS will also be communicated. Data from three large Phase III studies will highlight the efficacy of Gilenya in reducing the rate of brain volume loss, the best characterized MRI predictor of long-term disability. There will also be a presentation on the INFORMS study, which is evaluating Gilenya in patients with primary-progressive MS. This form of MS affects about 10% of people with MS and follows a steady course of worsening neurologic function for which there are no approved disease modifying treatments.